NBI-827104

DRUG3 trials

Sponsors

Neurocrine Biosciences

Conditions

Continuous Spike and Wave During SleepEpileptic EncephalopathyEssential Tremor

Phase 2

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

CompletedNCT04625101

Neurocrine BiosciencesContinuous Spike and Wave During Sleep, Epileptic Encephalopathy

Start: 2021-04-26End: 2022-10-11Updated: 2025-09-05

Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

CompletedNCT04880616

Neurocrine BiosciencesEssential Tremor

Start: 2021-04-20End: 2022-06-08Updated: 2022-07-12

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

TerminatedNCT05301894

Neurocrine BiosciencesContinuous Spike and Wave During Sleep, Epileptic Encephalopathy

Start: 2022-06-07End: 2025-01-27Updated: 2026-02-13